Wegovy Without Insurance: Current Self-Pay Options
Without insurance, compare the exact manufacturer self-pay offer and pharmacy quote for the formulation prescribed. The commercial copay program and an uninsured cash offer are different pathways; a retail list price is not every patient’s actual cash bill.
Current conditional self-pay prices
The current manufacturer display lists tablets at $149 for 1.5 mg, $199 for 4 mg and $299 for 9 or 25 mg per 30-tablet bottle. Injection self-pay offers list $349 per four-pen, 28-day supply for 0.25–2.4 mg or $399 for HD 7.2 mg. Eligible new injection-offer patients can instead pay $199 for each of the first two 0.25/0.5 mg fills completed by December 31, 2026; eligibility requires no Wegovy injection savings redemption in the preceding 365 days. A third fill uses standard pricing.
The self-pay terms prohibit seeking reimbursement or applying the expense toward insurance deductibles or out-of-pocket requirements. These medicine-only offers are conditional, may change and do not include every clinician, membership, lab or delivery charge.
Commercial copay savings are different
The commercial as-low-as-$25 offer requires eligible commercial coverage; it is not an uninsured $50–150 prescription or a $300-per-injection subsidy. Uninsured patients should read the separate self-pay terms instead. Eligibility for one program does not establish eligibility for every manufacturer offer.
Check the actual assistance product list
The official PAP product list does not list Wegovy. Do not promise free Wegovy from another product’s income rules or application process. An independent discount card is a separate pharmacy quote; no fixed percentage saving or universal best price was verified.
Add clinical access and recurring fees
Ask any local or telehealth service for the exact medicine, pharmacy, initial and recurring membership, visits, labs, supplies and cancellation terms. A low compounded-treatment rate is not a verified brand-Wegovy bundle. A prescription requires an appropriate evaluation; no universal same-day or 1–2-day prescription, shipment or first-dose route is established here.
Other medicines and compounds
Wegovy, Ozempic and other semaglutide products have different labels, formulations, doses and offers. Prices and savings eligibility are not identical by ingredient. The prescribed product label and clinician’s instructions govern any treatment change.
FDA’s current notice limits the role of compounded GLP-1 s to unmet medical needs. Compounds are not approved generic Wegovy, and accreditation does not guarantee individual preparation safety. This page gives no research-vial shopping, mixing instructions or fixed compound saving against an outdated list price.
Before the first fill
Confirm the written total and usable supply, eligibility, offer expiry and what a renewal costs. Keep the clinical follow-up and symptom-response plan. Do not reduce the prescribed dose, delay care or purchase extra medicine merely to match a promotion.
Related reading
- Wegovy Savings Card guide
- telehealth GLP-1 visit guide
- compounded semaglutide guide
- cheapest compounded semaglutide pricing guide
- complete semaglutide guide
- Wegovy Cost Breakdown: Full Pricing Guide
- Wegovy Cost With Insurance: Copay & Coverage
- Wegovy Savings Card: How to Apply & Save
- Wegovy Coupons & Discounts 2026
- Compounded Semaglutide: Safety & Quality
- Telehealth GLP-1 Visits: What to Expect
Frequently Asked Questions
Obtain a current pharmacy quote and compare applicable manufacturer self-pay terms for the actual formulation and strength. The retail list price and conditional self-pay offer are different.
The commercial copay offer requires eligible commercial coverage. Uninsured patients may use a separate self-pay pathway if eligible; that does not promise a $50–150 bill or a $300-per-injection benefit.
Clinical assessment, prescription, pharmacy processing and inventory determine timing. No universal 1–2-day route or free-assistance approval timeline was verified.
Compounded semaglutide is not approved generic Wegovy. Accreditation or licensing does not establish equivalence, patient suitability or safety of every preparation.
No fixed saving is supported against all current brand offers and complete care fees. Compare actual clinically appropriate quotes for the same supply period.
The current Novo Nordisk PAP product list does not list Wegovy. Another medicine’s income rule or free-drug process does not establish Wegovy assistance.
An appropriately licensed telehealth clinician may evaluate an uninsured patient. Verify actual availability, exact medicine, pharmacy, full fees and follow-up; no universal bundle or delivery time is established.
They have different labels, formulations and offers; prices and eligibility are not identical. Discuss appropriate treatment first and compare the actual current terms for that prescription.